SISVEL-INTERNATIONAL
19.7.2022 09:32:08 CEST | Business Wire | Press release
Sisvel International S.A. (“Sisvel”) today announced the launch of a patent pool on Wi-Fi 6 technology. The initial members of this pool will be Huawei, Mediatek, Philips, SK Telecom and Wilus. Huawei and Philips are also the first licensees of the pool. Along with the Wi-Fi 6 pool, Sisvel also debuted a new structured payment plan — the Licensing Incentive Framework for Technologies (LIFT).
Even before the official publication of the standard by IEEE, Wi-Fi 6 (802.11ax) has been pervasive in the market. Increased average throughput per user -the standard itself talks about a fourfold increase- and increased number of concurrent users in high density scenarios (offices, campuses, airports, stadiums, etc.) are among the main benefits of Wi-Fi 6 when compared to Wi-Fi 5. Wi-Fi 6 has brought wireless connectivity to a whole new level. Additional information about the technological advances of Wi-Fi 6 and how it enhances and enables existing and new applications can be found on Sisvel’s blog [https://www.sisvel.com/blog/wireless-communications ].
Sisvel is committed to create licensing solutions that work for both innovators and implementers. To facilitate early adoption of licenses, Sisvel created a new royalty scheme, the Licensing Incentive Framework for Technologies (or LIFT), which will be available to licensees of this new pool. “LIFT is the result of a two-year effort, specifically built to address the disadvantage that sometimes early licensees can feel and the “I don’t want to be the first” syndrome,” reveals Mattia Fogliacco, President of Sisvel International. “We are confident that LIFT will substantially help in fostering the creation of a level playing field,” he continues. Further information on LIFT can be found on Sisvel’s website [https://www.sisvel.com/licensing-programs/wireless-communications/wifi6/patent-pool/license-terms ] and blog [https://www.sisvel.com/blog/wireless-communications/lift-levelling-the-playing-field-for-early-licensees ].
“The patent pool will increase transparency of patent licensing and reduce licensing disputes in the field. Implementers can obtain a license under all patents in the pool at one time, which increases licensing efficiency and reduces licensing costs,” comments Alan Fan, Head of Huawei’s Intellectual Property Rights Department.
Steven Liu, Director at MediaTek states: “We support industry-driven licensing solutions that help to promote the adoption of new standards. We believe this group of industry participants, and with Sisvel as experienced administrator, can work together toward such goal.”
“Patent pools are the most efficient and transparent way to license Standard Essential Patents, reducing transaction costs and stimulating a level-playing field. For many years, Sisvel has been one of our partners in licensing audio/video codecs, and we are happy that we can now further expand our relationship into the Wi-Fi domain,” says Jako Eleveld, Head of IP Licensing at Royal Philips.
“SK Telecom is committed to always find the most efficient way to license its patents. We believe that this pool combines key patent owners, high quality assets and an innovative royalty scheme to align the interests of patent owners and implementors,” declares Hogeun Kim, Vice President of Corporate Legal Office at SK Telecom.
Wilus’ CEO, Jin Sam Kwak, explains that “Wilus endorses LIFT, the alternative scheme for sponsoring the adoption of this new technology for implementers. Adjusting royalty payments based on the global market penetration of Wi-Fi 6 licenses can incentivize adoption. With LIFT, the Wi-Fi 6 pool is made more attractive to potential licensees.”
Sisvel’s Wi-Fi Program Manager, Andrea Rombolà adds that “Licensing Wi-Fi technology has never been easy, but innovation has to be rewarded, because this is the only way to generate a virtuous circle to incentivize parties to innovate. Wi-Fi is such a key technology to our lives today, made ever so much more important by the pandemic and the associated work-from-home phenomena. This new pool represents a very efficient way to clear the rights of major owners of Wi-Fi 6 standard essential patents.” Mattia Fogliacco continues: “During the past two years of facilitation, we have created a framework that we feel will benefit the Markets for Technology as a whole, removing friction and aligning interests of innovators and implementers. We trust that this, together with the quality of the IP contributed by the participating patent owners, will quickly attract additional licensees and possibly additional patent owners.”
Sisvel is making the valuable portfolios included in the pool accessible on fair, reasonable, and non-discriminatory terms and conditions, by offering a royalty-bearing, non-transferable, non-assignable, non-exclusive license, with no right to grant sublicenses, under the participating patent owners’ patent portfolios essential to the 802.11ax specification.
Further information about the terms and conditions of this license offer is available on Sisvel’s website [https://www.sisvel.com/licensing-programs/wireless-communications/wifi6/patent-pool/introduction ]. For more details you may contact Sisvel at the following e-mail address WiFi6-Licensing@sisvel.com .
About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in fostering innovation and managing IP. The group identifies, evaluates and maximises the value of IP assets for its partners around the world, providing firms with a revenue stream which can be reinvested in innovation for the generation of future revenues. Sisvel has more than 40 years’ experience in the management of successful patent portfolios, including those relating to audio compression standards (MP3 and MPEG audio), as well as broadcasting and digital terrestrial television standards maintained by the Digital Video Broadcasting Project. Sisvel operates patent pools and joint licensing programmes in the fields of mobile communication, wireless local area networking 802.11, video coding, digital video broadcasting, recommendation engines and broadband access to data networks.
www.sisvel.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220719005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
